With the launch, Spain becomes the 26th country in which Insulet sells Omnipod and the 20th reached by Omnipod 5, the company’s latest-generation patch-based automated insulin delivery system.
Omnipod 5 became the world’s first available tubeless, wearable, automated insulin delivery system when it received FDA clearance in January 2022. The waterproof, discreet system helps simplify diabetes management by automatically adjusting insulin every five minutes to help improve glycemic outcomes. It communicates with a continuous glucose monitor (CGM) to proactively correct for highs and protect against lows. Omnipod 5 delivers improved time in range and reduced HbA1c without requiring multiple daily injections (MDI).
Insulet said it made Omnipod 5 available in Spain for people aged two years and older with type 1 diabetes. It has compatibility with the Abbott FreeStyle Libre 2 Plus and Dexcom G7 sensors.
More about Omnipod Discover
Omnipod Discover, a proprietary and retrospective data analytics and reporting platform, was designed for Omnipod 5 users, their caregivers and healthcare providers. It streamlines the analysis of glucose and insulin delivery data to deliver meaningful insights.
Insulet said Omnipod Discover transforms complex information into clear, relevant trends and recommendations to inform diabetes management. Using a web-based, intuitive display, the platform shows how the Omnipod 5 algorithm automates insulin delivery. It enables the understanding of trends to make decisions confidently, the company said.
With Omnipod Discover, users can access their data with insights in a simplified way that empowers them to understand and manage their diabetes.
Insulet launched Omnipod Discover in the Middle East earlier this year. It plans to expand into additional countries in the coming year.
Commentary from Insulet officials
Pat Crannell, Insulet SVP and international GM, said:
“We’re thrilled to introduce Omnipod 5 with Omnipod Discover to Spain—an important and dynamic market where we see a meaningful opportunity to support people with diabetes and the healthcare professionals who care for them. Our continued international expansion—including the launch of Omnipod 5 in 15 countries over the last 18 months—reflects the strength of our global growth strategy and passion of our teams. Every new market brings us closer to a world where diabetes demands less.”
Dr. Rafael Bravo, endocrinology specialist and Insulet VP for global medical affairs, said:
“Insulet understands that many people living with type 1 diabetes in Spain want tools that are simple and more intuitive, helping them feel safer and more confident. That is why the arrival of Omnipod 5 and Omnipod Discover are important steps towards easing the day-to-day demands of diabetes management while improving the quality of life for individuals and their families.”
